Quantitative validation of preclinical brain tumor perfusion MRI using co-injected radioactive MR contrast agent analogs

Ziel/Aim Dynamic contrast-enhanced (DCE) MRI allows to estimate perfusion parameters in-vivo based on quantification of the dynamic tissue and arterial blood contrast agent (CA) concentrations (arterial input function, AIF) and pharmacokinetic modeling. However, validation of MR CA concentration estimates is rarely performed. In this study, we validated DCE-MRI with co-injected radioactive contrast agent analogues and by mass spectrometry.